MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Operating Income 2011-2026 | ADMP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.1 M | -32.1 M | -36.3 M | -29.4 M | -39.5 M | -24.8 M | -25.2 M | -13.9 M | -9.72 M | -3.22 M | -4.82 M | -6.24 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.22 M | -39.5 M | -20.8 M |
Quarterly Operating Income Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.27 M | -6.43 M | - | -4.63 M | -8.18 M | -7.91 M | - | -10.2 M | -7.65 M | -6.22 M | - | -5.5 M | -11.2 M | -10.3 M | - | -7.01 M | -7.75 M | -8.94 M | - | -8.91 M | -9.67 M | -7.61 M | - | -5.8 M | -4.92 M | -5.71 M | - | -6.58 M | -7.43 M | -6.02 M | - | -3.31 M | -3.53 M | -4.15 M | - | -1.94 M | -2.75 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -748 K | -11.2 M | -5.29 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 4.28 | 2.15 % | $ 60.2 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.67 | 1.61 % | $ 2.07 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.15 | -4.17 % | $ 124 M | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 40.48 | -2.25 % | $ 1.49 B | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
-32.7 M | $ 5.27 | 0.96 % | $ 340 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.47 | -2.65 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.23 | 2.49 % | $ 421 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.4 | 0.42 % | $ 316 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 25.41 | -0.55 % | $ 1.18 B | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.91 | -6.19 % | $ 3.92 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.04 | - | $ 116 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.45 | -0.67 % | $ 652 M | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 1.04 | -6.31 % | $ 1.29 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.24 | 2.99 % | $ 286 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.56 | -4.79 % | $ 4.05 B | Canada |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.99 | -1.42 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.29 | -2.14 % | $ 309 M | USA |
 |
Viatris
VTRS
|
766 M | $ 14.82 | 0.07 % | $ 17.8 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.42 | -2.56 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.89 | 5.24 % | $ 32 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.56 | -4.13 % | $ 2.4 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.1 | 1.45 % | $ 24.3 M | USA |